Emblaveo will be available in the third quarter of 2025 to treat patients with intra-abdominal infections, a common cause of sepsis in the intensive care unit.

It's the first and only such therapy approved to fight antimicrobial resistance, or AMR, in bacterial infections.

It has in vitro activity against a broad range of gram-positive and gram-negative aerobes but no activity against anaerobes. A fluorine atom at position six is responsible for increased potency ...

soln; contains benzalkonium chloride. Trimethoprim is a synthetic antibacterial drug active against a wide variety of aerobic gram-positive and gram-negative ophthalmic pathogens. Trimethoprim ...